BioMarin Pharmaceutical Gross Profit 2006-2019 | BMRN

BioMarin Pharmaceutical annual/quarterly gross profit history and growth rate from 2006 to 2019. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • BioMarin Pharmaceutical gross profit for the quarter ending March 31, 2019 was $0.312B, a 7.02% increase year-over-year.
  • BioMarin Pharmaceutical gross profit for the twelve months ending March 31, 2019 was $1.196B, a 7.86% increase year-over-year.
  • BioMarin Pharmaceutical annual gross profit for 2018 was $1.176B, a 9.71% increase from 2017.
  • BioMarin Pharmaceutical annual gross profit for 2017 was $1.072B, a 18.15% increase from 2016.
  • BioMarin Pharmaceutical annual gross profit for 2016 was $0.907B, a 22.95% increase from 2015.
BioMarin Pharmaceutical Annual Gross Profit
(Millions of US $)
2018 $1,176
2017 $1,072
2016 $907
2015 $738
2014 $627
2013 $460
2012 $409
2011 $357
2010 $306
2009 $259
2008 $244
2007 $103
2006 $75
2005 $23
BioMarin Pharmaceutical Quarterly Gross Profit
(Millions of US $)
Q1 2019 $312
Q4 2018 $278
Q3 2018 $313
Q2 2018 $294
Q1 2018 $291
Q4 2017 $282
Q3 2017 $275
Q2 2017 $261
Q1 2017 $254
Q4 2016 $236
Q3 2016 $229
Q2 2016 $249
Q1 2016 $194
Q4 2015 $180
Q3 2015 $174
Q2 2015 $212
Q1 2015 $172
Q4 2014 $191
Q3 2014 $147
Q2 2014 $161
Q1 2014 $129
Q4 2013 $130
Q3 2013 $109
Q2 2013 $114
Q1 2013 $107
Q4 2012 $105
Q3 2012 $103
Q2 2012 $100
Q1 2012 $100
Q4 2011 $86
Q3 2011 $91
Q2 2011 $91
Q1 2011 $89
Q4 2010 $81
Q3 2010 $80
Q2 2010 $78
Q1 2010 $68
Q4 2009 $70
Q3 2009 $66
Q2 2009 $63
Q1 2009 $60
Q4 2008 $88
Q3 2008 $59
Q2 2008 $55
Q1 2008 $43
Q4 2007 $40
Q3 2007 $21
Q2 2007 $24
Q1 2007 $19
Q4 2006 $2
Q3 2006 $22
Q2 2006 $23
Q1 2006 $12
Q4 2005 $-1
Q3 2005 $7
Q2 2005 $3
Q1 2005 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $14.768B $1.491B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $107.995B 12.21
Gilead Sciences (GILD) United States $85.316B 10.36
Celgene (CELG) United States $64.087B 10.86
Vertex Pharmaceuticals (VRTX) United States $45.369B 54.84
Illumina (ILMN) United States $44.526B 51.60
Biogen (BIIB) United States $44.487B 8.44
CSL (CSLLY) Australia $35.586B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.719B 15.38
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.673B 15.66
Incyte (INCY) United States $17.204B 69.76
Exact Sciences (EXAS) United States $15.024B 0.00
SINO PHARMACEUT (SBMFF) China $14.154B 0.00
Seattle Genetics (SGEN) United States $12.157B 0.00
Sarepta Therapeutics (SRPT) United States $11.420B 0.00
Genmab (GNMSF) Denmark $11.291B 57.40
Array BioPharma (ARRY) United States $10.322B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $8.926B 29.32
Galapagos (GLPG) Belgium $8.704B 0.00
Guardant Health (GH) United States $8.043B 0.00
Bio-Techne Corp (TECH) United States $7.954B 54.27
Alnylam Pharmaceuticals (ALNY) United States $7.743B 0.00
Bluebird Bio (BLUE) United States $7.687B 0.00
Amarin (AMRN) Ireland $6.968B 0.00
Exelixis (EXEL) United States $6.551B 16.70
BeiGene (BGNE) Cayman Islands $5.653B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.786B 0.00
Ascendis Pharma (ASND) Denmark $4.751B 0.00
Blueprint Medicines (BPMC) United States $4.706B 0.00
Moderna (MRNA) United States $4.616B 0.00
Horizon Pharma Public (HZNP) Ireland $4.491B 11.57
Repligen (RGEN) United States $4.118B 102.59
Spark Therapeutics (ONCE) United States $3.727B 0.00
Mirati Therapeutics (MRTX) United States $3.724B 0.00
ACADIA Pharmaceuticals (ACAD) United States $3.686B 0.00
China Biologic Products (CBPO) China $3.670B 23.31
Alkermes (ALKS) Ireland $3.623B 0.00
MorphoSys AG (MOR) Germany $3.446B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.416B 0.00
Arena Pharmaceuticals (ARNA) United States $3.040B 6.18
Amicus Therapeutics (FOLD) United States $2.924B 0.00
Immunomedics (IMMU) United States $2.871B 0.00
UniQure (QURE) Netherlands $2.738B 0.00
Medicines (MDCO) United States $2.704B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.605B 0.00
Reata Pharmaceuticals (RETA) United States $2.529B 0.00
Halozyme Therapeutics (HALO) United States $2.439B 0.00
MyoKardia (MYOK) United States $2.295B 0.00
NeoGenomics (NEO) United States $2.282B 149.38
Nabriva Therapeutics AG (NBRV) Ireland $2.260B 0.00
Ligand Pharmaceuticals (LGND) United States $2.210B 18.31
Acceleron Pharma (XLRN) United States $2.199B 0.00
Emergent Biosolutions (EBS) United States $2.180B 18.93
Zai Lab (ZLAB) China $2.109B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.078B 0.00
Akcea Therapeutics (AKCA) United States $2.063B 0.00
Genomic Health (GHDX) United States $2.044B 43.42
Myriad Genetics (MYGN) United States $1.930B 19.20
Denali Therapeutics (DNLI) United States $1.917B 0.00
REGENXBIO (RGNX) United States $1.749B 0.00
Insmed (INSM) United States $1.672B 0.00
Cambrex (CBM) United States $1.510B 19.10
AnaptysBio (ANAB) United States $1.457B 0.00
Fate Therapeutics (FATE) United States $1.451B 0.00
RA PHARMCTL INC (RARX) United States $1.379B 0.00
Innoviva (INVA) United States $1.365B 3.78
Sangamo Therapeutics (SGMO) United States $1.364B 0.00
Athenex (ATNX) United States $1.286B 0.00
Alector (ALEC) United States $1.256B 0.00
Coherus BioSciences (CHRS) United States $1.233B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.187B 0.00
Editas Medicine (EDIT) United States $1.184B 0.00
Epizyme (EPZM) United States $1.142B 0.00
Cara Therapeutics (CARA) United States $1.070B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.023B 0.00
Codexis (CDXS) United States $1.022B 0.00
Twist Bioscience (TWST) United States $0.978B 0.00
Adverum Biotechnologies (ADVM) United States $0.978B 0.00
Principia Biopharma (PRNB) United States $0.974B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.26
Momenta Pharmaceuticals (MNTA) United States $0.959B 0.00
Zymeworks (ZYME) Canada $0.940B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.924B 0.00
WAVE Life Sciences (WVE) Singapore $0.907B 0.00
Retrophin (RTRX) United States $0.879B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.866B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Vericel (VCEL) United States $0.853B 0.00
Arvinas (ARVN) United States $0.772B 0.00
Intellia Therapeutics (NTLA) United States $0.763B 0.00
Precision BioSciences (DTIL) United States $0.746B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.704B 33.22
Zealand Pharma (ZEAL) Denmark $0.704B 8.22
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Cytokineticsorporated (CYTK) United States $0.670B 0.00
Clovis Oncology (CLVS) United States $0.654B 0.00
Intra-Cellular Therapies (ITCI) United States $0.643B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.639B 0.00
Cellectis S.A (CLLS) France $0.635B 0.00
Heska (HSKA) United States $0.622B 63.73
DBV Technologies S.A (DBVT) France $0.596B 0.00
Anika Therapeutics (ANIK) United States $0.581B 19.84
Stemline Therapeutics (STML) United States $0.580B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.569B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.560B 0.00
Revance Therapeutics (RVNC) United States $0.557B 0.00
CytomX Therapeutics (CTMX) United States $0.549B 0.00
MiMedx (MDXG) United States $0.525B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
Mesoblast (MESO) Australia $0.494B 0.00
PHARMA MAR SA (PHMMF) Spain $0.453B 0.00
UROGEN PHARMA (URGN) United States $0.445B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.442B 0.00
Puma Biotechnology (PBYI) United States $0.405B 0.00
AC Immune SA (ACIU) Switzerland $0.398B 25.61
Prothena (PRTA) Ireland $0.389B 0.00
PDL BioPharma (PDLI) United States $0.379B 9.06
Arcus Biosciences (RCUS) United States $0.376B 0.00
Gritstone Oncology (GRTS) United States $0.372B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Biofrontera AG (BFRA) Germany $0.369B 0.00
Scholar Rock Holding (SRRK) United States $0.361B 0.00
Bellus Health (BLUSF) Canada $0.361B 0.00
Albireo Pharma (ALBO) United States $0.354B 0.00
Merus (MRUS) Netherlands $0.352B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.351B 0.00
Prometic Life Sciences (PFSCD) Canada $0.349B 0.00
BioDelivery Sciences (BDSI) United States $0.348B 0.00
Avid Bioservices (CDMO) United States $0.347B 0.00
Kadmon Holdings (KDMN) United States $0.344B 0.00
Starpharma Holdings (SPHRY) Australia $0.343B 0.00
Agenus (AGEN) United States $0.340B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.333B 0.00
Acorda Therapeutics (ACOR) United States $0.332B 5.85
Senesco Technologies (ELOX) United States $0.331B 0.00
Theratechnologies (THERF) Canada $0.330B 0.00
Syros Pharmaceuticals (SYRS) United States $0.322B 0.00
Protagonist Therapeutics (PTGX) United States $0.310B 0.00
Sorrento Therapeutics (SRNE) United States $0.307B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.292B 0.00
Cellular Biomedicine (CBMG) United States $0.275B 0.00
Kindred Biosciences (KIN) United States $0.269B 0.00
Inovio Pharmaceuticals (INO) United States $0.266B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.261B 0.00
Sutro Biopharma (STRO) United States $0.253B 0.00
ChromaDex (CDXC) United States $0.253B 0.00
PHASEBIO PHARMA (PHAS) United States $0.249B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.248B 0.00
Dynavax Technologies (DVAX) United States $0.247B 0.00
Kamada (KMDA) Israel $0.241B 9.36
Athersys (ATHX) United States $0.235B 0.00
ADMA Biologics Inc (ADMA) United States $0.232B 0.00
Geron (GERN) United States $0.231B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.222B 0.00
Cel-Sci (CVM) United States $0.214B 0.00
CorMedix Inc (CRMD) United States $0.214B 0.00
Palatin Technologies (PTN) United States $0.211B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.206B 0.00
Cerecor (CERC) United States $0.199B 0.00
Five Prime Therapeutics (FPRX) United States $0.198B 0.00
Synlogic (SYBX) United States $0.196B 0.00
MannKind (MNKD) United States $0.195B 0.00
Abeona Therapeutics (ABEO) United States $0.193B 0.00
Mersana Therapeutics (MRSN) United States $0.191B 0.00
Affimed (AFMD) Germany $0.190B 0.00
Pfenex (PFNX) United States $0.187B 0.00
OSMOTICA PHARM (OSMT) United States $0.185B 0.00
Spero Therapeutics (SPRO) United States $0.185B 0.00
POXEL SA FRANCE (PXXLF) $0.184B 0.00
Compugen (CGEN) Israel $0.183B 0.00
Arsanis (XFOR) United States $0.180B 0.00
Enzo Biochem (ENZ) United States $0.179B 0.00
BioTime (BTX) United States $0.169B 11.30
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
Nicox SA (NICXF) France $0.162B 0.00
XOMA (XOMA) United States $0.159B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.158B 0.00
Strongbridge Biopharma (SBBP) United States $0.157B 9.03
Cue Biopharma (CUE) United States $0.151B 0.00
Liquidia Technologies (LQDA) United States $0.144B 0.00
OvaScience (MLND) United States $0.142B 0.00
TOCAGEN INC (TOCA) United States $0.141B 0.00
Adocia (ADOCY) France $0.140B 0.00
Celyad SA (CYAD) Belgium $0.139B 0.00
Northwest Biotherapeutics (NWBO) United States $0.134B 0.00
Dyadic (DYAI) United States $0.133B 0.00
Seres Therapeutics (MCRB) United States $0.128B 0.00
NantKwest (NK) United States $0.125B 0.00
Aptinyx (APTX) United States $0.123B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.122B 0.00
Alcobra (ARCT) United States $0.119B 0.00
Aduro Biotech (ADRO) United States $0.118B 0.00
Arbutus Biopharma (ABUS) Canada $0.115B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.112B 0.00
Verastem (VSTM) United States $0.110B 0.00
Checkpoint Therapeutics (CKPT) United States $0.110B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.109B 0.00
Menlo Therapeutics (MNLO) United States $0.108B 0.00
Novavax (NVAX) United States $0.107B 0.00
SESEN BIO, INC (SESN) United States $0.101B 0.00
Catalyst Biosciences (CBIO) United States $0.101B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.101B 0.00
Trevena (TRVN) United States $0.095B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.094B 0.00
Fortress Biotech (FBIO) United States $0.089B 0.00
Pluristem Therapeutics (PSTI) Israel $0.089B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.085B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.084B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.084B 0.00
Unum Therapeutics (UMRX) United States $0.079B 0.00
Selecta Biosciences (SELB) United States $0.078B 0.00
Curis (CRIS) United States $0.078B 0.00
AquaBounty Technologies (AQB) United States $0.076B 0.00
VBI Vaccines (VBIV) United States $0.076B 0.00
VTv Therapeutics (VTVT) United States $0.075B 0.00
Idera Pharmaceuticals (IDRA) United States $0.073B 0.00
Orgenesis (ORGS) United States $0.073B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.072B 0.00
Applied Genetic Technologies (AGTC) United States $0.071B 38.80
Signal Genetics (MGEN) United States $0.070B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.065B 0.00
Organovo Holdings (ONVO) United States $0.064B 0.00
ARAVIVE, INC (ARAV) United States $0.063B 0.00
Alimera Sciences (ALIM) United States $0.061B 0.00
Antibe Therapeutics (ATBPF) Canada $0.060B 0.00
Protalix BioTherapeutics (PLX) Israel $0.059B 0.00
Prima BioMed (IMMP) Australia $0.059B 0.00
Invo BioScience (IVOB) United States $0.055B 0.00
NewLink Genetics (NLNK) United States $0.054B 0.00
Oncobiologics (OTLK) United States $0.051B 0.00